The present invention relates to a wound dressing comprising hyaluronic acid-calcium and polylysine, and a manufacturing method therefor, the method comprising: (1) a step for adjusting each of the pH values of a hyaluronic acid-calcium salt and a polylysine aqueous solution to 8.4 or higher, and then mixing the hyaluronic acid-calcium salt and the polylysine aqueous solution to obtain a mixture liquid; and (2) obtaining a wound dressing from the mixture liquid obtained in Step (1).

The present disclosure relates to a dry composition which reconstitutes without mechanical mixing to form a flowable paste having a soft and light consistency suitable for use in haemostasis and wound healing procedures upon addition of an aqueous medium. The disclosure further relates to methods of preparing the dry composition, methods for reconstituting the dry composition and medical use of the composition.

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived grown factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described.

A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold.

The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.

A moisture absorbent material capable of biomedical application to absorb and manage bodily fluids such as blood and wound exudate as a wound or first aid dressing or bandage. The material is a psyllium foam based material offering high absorbency and potentially haemostatic characteristics.

The present invention relates to a covalently cross-linked hyaluronic acid aerogel, a hydrogel, and a preparation method thereof. The method includes steps of: taking hyaluronic acid as a raw material to prepare a hyaluronic acid aqueous solution; taking 1,4-butanediol diglycidyl ether, ethylene glycol diglycidyl ether, or polyethylene glycol diglycidyl ether as a crosslinking agent; promoting a chemical crosslinking through covalent bonds between the crosslinking agent and the hyaluronic acid by a freeze-drying technique to obtain a covalently cross-linked hyaluronic acid aerogel; furthermore, soaking the covalently cross-linked hyaluronic acid aerogel in purified water, which absorbing water and swelling to obtain a covalently cross-linked hyaluronic acid hydrogel. The covalently cross-linked hyaluronic acid aerogel has good liquid absorption properties, and can quickly absorb water and swell to the covalently cross-linked hyaluronic acid hydrogel.

The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of said formulation to said ulcer; followed by (b) application of a dressing, and wherein said application of said formulation provides for a dose of LL-37 at the wound site that is below about 80 g of LL-37 applied per cm2 of wound area, and/or below about 26.7 g of LL-37 applied per cm2 of wound area, per day of treatment.

An immune-modulating biomaterial comprising a hydrogel scaffold coupled to D-amino acid containing peptides having unexpected properties in vivo is described. For example, certain inflammatory reactions in vivo are significantly increased around the D-peptide containing particles of hydrogel scaffold as compared to particles that contain both L and D peptides or L peptides alone. In addition, these D-peptide compositions are further observed to enhance wound healing and improve the tensile strength of healed tissues. For these and other reasons, the D-amino acid hydrogel materials disclosed herein are useful in a number of methodologies that seek to modulate the immune response and/or wound healing.